Mood disorders in systemic lupus erythematosus: Results from an international inception cohort study

Arthritis and Rheumatology

Volumn 67, Issue 7, 2015, Pages 1837-1847

  Hanly, John G ^a   Su, Li ^b   Urowitz, Murray B ^c   Romero Diaz, Juanita ^d   Gordon, Caroline ^e   Bae, Sang Cheol ^f   Bernatsky, Sasha ^g   Clarke, Ann E ^h   Wallace, Daniel J ⁱ   Merrill, Joan T ^j   Isenberg, David A ^k   Rahman, Anisur ^k   Ginzler, Ellen M ^l   Petri, Michelle ^m   Bruce, Ian N ⁿ   Dooley, M A ^o   Fortin, Paul ^p   Gladman, Dafna D ^c   Sanchez Guerrero, Jorge ^c   Steinsson, Kristjan ^q   Ramsey Goldman, Rosalind ^r   Khamashta, Munther A ^s   Aranow, Cynthia ^t   Alarcón, Graciela S ^t   Fessler, Barri J ^u   Manzi, Susan ^v   Nived, Ola ^w   Sturfelt, Gunnar K ^w   Zoma, Asad A ^x   Van Vollenhoven, Ronald F ^y   Ramos Casals, Manuel ^z   Ruiz Irastorza, Guillermo ^aa   Lim, S Sam ^ab   Kalunian, Kenneth C ^ac   Inanc, Murat ^ad   Kamen, Diane L ^ae   Peschken, Christine A ^af   Jacobsen, Soren ^ag   Askanase, Anca ^ah   Theriault, Chris ^a   Thompson, Kara ^a   Farewell, Vernon ^b   more..

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l SUNY DOWNSTATE MEDICAL CENTER   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o UNIVERSITY OF NORTH CAROLINA   (United States)

^p LAVAL UNIVERSITY   (Canada)

^q LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^r NORTHWESTERN UNIVERSITY   (United States)

^s ST THOMAS HOSPITAL   (United Kingdom)

^t FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^u UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^v UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^w LUND UNIVERSITY HOSPITAL   (Sweden)

^x HAIRMYRES HOSPITAL   (United Kingdom)

^y KAROLINSKA INSTITUTE   (Sweden)

^z HOSPITAL CLÍNIC   (Spain)

^aa UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^ab EMORY UNIVERSITY   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad ISTANBUL UNIVERSITY   (Turkey)

^ae MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^af UNIVERSITY OF MANITOBA   (Canada)

^ag University of Copenhagen   (Denmark)

^ah NEW YORK UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT;

ADULT; ARTICLE; DEPRESSION; DISEASE ACTIVITY SCORE; DISEASE DURATION; DSM-IV; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MENTAL HEALTH; MOOD DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; BLOOD; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; ETHNOLOGY; HISPANIC; IMMUNOLOGY; INCIDENCE; INTERNATIONAL COOPERATION; MIDDLE AGED; MOOD DISORDERS; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGY; REGRESSION ANALYSIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; INTERNATIONALITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MOOD DISORDERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGRESSION ANALYSIS;

EID: 84933059999     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39111     Document Type: Article

References (36)

1. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A., The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57: 496-500.
2. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al., Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20.
3. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K., Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156-62.
4. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Mathieu A, Hughes GR., Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
5. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al., The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536-42.
6. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al., Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007; 56: 265-73.
7. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al., Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 529-35.
8. Isenberg D, Ramsey-Goldman R., Systemic Lupus International Collaborating Group: onwards and upwards? Lupus 2006; 15: 606-7.
9. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
10. Gladman DD, Ibanez D, Urowitz MB., Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91.
11. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al., The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
12. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
13. Ware JE Jr, Sherbourne CD., The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
14. Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae SC, Gordon C, et al., Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008; 59: 721-9.
15. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al., Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001; 45: 419-23.
16. Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, et al., SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 961-7.
17. Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, et al., Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26: 97-102.
18. Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, et al., Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81: 748-57.
19. Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB., High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24: 1083-8.
20. Erkan D, Zhang HW, Shriky RC, Merrill JT., Dual antibody reactivity to β2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002; 11: 215-20.
21. Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC, et al., Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843-53.
22. Ayuso-Mateos JL, Vazquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, et al., Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry 2001; 179: 308-16.
23. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al., The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12: 3-21.
24. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al., Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-9.
25. Matcham F, Rayner L, Steer S, Hotopf M., The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136-48.
26. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al., Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int 2013; 84: 179-91.
27. Kellner ES, Lee PY, Li Y, Switanek J, Zhuang H, Segal MS, et al., Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus. J Neuroimmunol 2010; 223: 13-9.
28. Huang X, Magder LS, Petri M., Predictors of incident depression in systemic lupus erythematosus. J Rheumatol 2014; 41: 1823-33.
29. Thumboo J, Fong KY, Chan SP, Leong KH, Feng PH, Thio ST, et al., A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000; 27: 1414-20.
30. Strand V, Crawford B., Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005; 5: 317-26.
31. Hanly JG, Su L, Omisade A, Farewell VT, Fisk JD., Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol 2012; 39: 1371-7.
32. Vogel A, Bhattacharya S, Larsen JL, Jacobsen S., Do subjective cognitive complaints correlate with cognitive impairment in systemic lupus erythematosus? A Danish outpatient study. Lupus 2011; 20: 35-43.
33. Thames AD, Becker BW, Marcotte TD, Hines LJ, Foley JM, Ramezani A, et al., Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol 2011; 25: 224-43.
34. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al., Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009; 61: 240-6.
35. Van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, et al., Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus 2013; 22: 1462-9.
36. Thombs BD, Ziegelstein RC., Depression screening in primary care: why the Canadian task force on preventive health care did the right thing. Can J Psychiatry 2013; 58: 692-6.